DAVID POORVIN, PH.D.

Corporate Board Profile

Tech Score: 0/100

ENANTA PHARMACEUTICALS INC

Filing Date	Source Excerpt
2014-01-10	Two of our current Class I directors, Marc Goldberg and David Poorvin, at their request are not being nominated for reelection at the upcoming annual meeting and will end their term of office effective as of February 5, 2014... The members of our Audit Committee are Drs. Afting and Poorvin and Messrs. Buckley and Goldberg... The members of our Nominating and Corporate Governance Committee are Drs. Afting, Carter and Poorvin and Messrs. Buckley, Goldberg and Vance... Total ($) 83,017.

Filing Date

Source Excerpt

2014-01-10

Two of our current Class I directors, Marc Goldberg and David Poorvin, at their request are not being nominated for reelection at the upcoming annual meeting and will end their term of office effective as of February 5, 2014... The members of our Audit Committee are Drs. Afting and Poorvin and Messrs. Buckley and Goldberg... The members of our Nominating and Corporate Governance Committee are Drs. Afting, Carter and Poorvin and Messrs. Buckley, Goldberg and Vance... Total ($) 83,017.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-06-14